BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,140 filers reported holding BAXTER INTL INC in Q4 2021. The put-call ratio across all filers is 1.40 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GENERATION INVESTMENT MANAGEMENT LLP | 21,171,371 | $1,817,350,000 | 7.47% |
| Soditic Asset Management LLP | 147,620 | $12,672,000 | 6.53% |
| NUANCE INVESTMENTS, LLC | 4,084,218 | $350,589,000 | 6.17% |
| PRAGMA GESTAO DE PATRIMONIO LTD | 145,000 | $12,447 | 5.96% |
| Veritas Asset Management LLP | 12,222,261 | $1,049,159,000 | 5.89% |
| Pavadi Capital LLC | 72,782 | $6,248,000 | 4.74% |
| Sonen Capital LLC | 48,907 | $4,198,000 | 4.06% |
| Glenview Capital Management | 2,182,422 | $187,339,000 | 3.99% |
| Dash Acquisitions Inc. | 103,963 | $8,924,000 | 3.87% |
| Avidity Partners Management LP | 1,765,000 | $151,508,000 | 3.21% |
| Dundas Partners LLP | 287,608 | $24,880,000 | 3.09% |
| TSFG, LLC | 102,243 | $8,777,000 | 3.05% |
| Haverford Financial Services, Inc. | 152,738 | $13,111,000 | 2.97% |
| Cincinnati Specialty Underwriters Insurance CO | 96,500 | $8,284,000 | 2.89% |
| Sivik Global Healthcare LLC | 75,000 | $6,438,000 | 2.76% |
| STONERIDGE INVESTMENT PARTNERS LLC | 67,183 | $5,767,000 | 2.66% |
| PENSIOENFONDS RAIL & OV | 1,237,600 | $106,582,000 | 2.52% |
| CINCINNATI FINANCIAL CORP | 1,370,648 | $117,656,000 | 2.46% |
| Foyston, Gordon, & Payne Inc | 120,372 | $10,333,000 | 2.41% |
| Ignite Planners, LLC | 37,671 | $3,247,000 | 2.11% |
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BAXTER INTL INC's shareholders in Q4 2021. To view BAXTER INTL INC's shareholder history, click here.